newsfilter
← Latest News
GlobeNewswire·

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YDES
  • YD Bio Limited and affiliate EG BioMed Co., Ltd. concluded their participation at BIO Asia-Taiwan 2026 held on July 19, 2026, at the Washington State Pavilion in Taiwan.
  • The companies showcased advancements in ophthalmic regenerative medicine, DNA-based cancer detection, & U.S. market entry services for life science partners.
  • Exovisse™ Eye Care, a partnership with 3D Global Biotech Inc., features preservative-free artificial tears & contact lenses that are FDA-compliant & authorized for nationwide U.S. sale.
  • Limbal Stem Cell (LSC) Exosome Therapy is in development to treat ocular surface diseases, with LSC materials registered in the FDA Drug Master File & an IND application for dry eye disease expected in 2026.
  • Initial human trials for the LSC therapy are slated for 2027, though the therapy remains in development & is not yet FDA approved.
  • EG BioMed US operates a CLIA-certified & CAP-accredited laboratory in Bothell, Washington, specializing in DNA methylation-based cancer detection & AI-driven biomarker analysis.
  • Following recent license approvals, EG BioMed US's operational footprint spans 47 U.S. states, Washington, D.C., Guam, the U.S. Virgin Islands, & American Samoa.
  • The laboratory's blood-based testing services screen for pancreatic, colorectal, breast, & liver cancers, subject to local regulatory requirements.
  • YD Bio introduced a Regulatory & Laboratory Setup Platform to assist Taiwan-based companies with CLIA/CAP certification & LDT development based on FDA guidelines.
  • An Integrated CRO Services platform was launched to guide partners through clinical trial processes, including research design, subject recruitment, & FDA regulatory submissions.
  • The companies engaged with over 30 prospective partners from Taiwan, Hong Kong, & global markets during the four-day event.
  • Key outcomes included strong interest in Exovisse™ trial collaborations & distribution, as well as inquiries regarding EG BioMed's laboratory network & cancer monitoring services.
  • YD Bio announced a non-binding Memorandum of Understanding to merge with EG BioMed in January 2026, with the transaction anticipated to close in 2026 subject to customary conditions.
  • Dr. Ethan Shen, Founder & CEO of YD Bio, emphasized the company's integrated platform spanning ophthalmic products, cancer diagnostics, & U.S. market bridging services.
  • Professor Lin Jo-Kai, Chief Research Officer of EG BioMed, highlighted the integration of clinical lab capabilities with telehealth to streamline patient care from consultation to follow-up.